Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Novo Nordisk A/S (ADR) (NVO) Revisits New Strategy To Deal With U.S Payers

Novo Nordisk A/S (ADR) (NYSE:NVO) incoming President and CEO Lars Fruergaard Jørgensen is slated to start his leadership roles in the New Year. However, it seems he is raring to go given that he is already aligning on how to restructure the company’s R&D priorities. This comes at a time when the diabetes giant has put a halt on the development of an oral form of insulin and instead choosing to refocus on its pipeline, which has more reliance on in-licensing early stage projects.

While it will also consider external academic collaborators, the Danish pharma aim is to put more emphasis on diabetes and obesity adjacent conditions. They include cardiovascular and chronic kidney disease as well as nonalcoholic steatohepatitis (NASH).

pharmacist, worker, shelves, business, counter, glasses, attractive, medical, competence, chemist, adult, clinic, drugstore, selling, female, consultation, medicine, coat

racorn/Shutterstock.com

Novo Nordisk A/S (ADR) (NYSE:NVO) Is Seeking Solution To U.S. Payer Difficulties

Jørgensen’s vision for a new Novo Nordisk will be interesting as the company has been struggling with payer problems in the U.S. which have resulted in worse-than-expected performance for its modern insulin. They have also hit at product pricing. The pharma’s argument is that payers are not supportive of the cost-effectiveness of oral insulin hence the long-standing complexity associated with its development.

However, as Novo Nordisk CSO and EVP Mads Krogsgaard Thomsen outlined, “We will seek to move into adjacent areas, areas that are part of and yet go beyond diabetes. These include NASH-Nonalcoholic Steatohepatitis proved to be kicked off by a Phase II trial with the semaglutide later this year, but also the buildup of the research pipeline.”

Revisit Of Research Strategy Prudent

The company’s complete retreat on oral insulin may be surprising but nonetheless Thomsen emphasizes that it is all about having a favorable payer environment, which will facilitate high innovation threshold that will justify new projects. Thus the R&D management and executive teams must go back to the drawing board. Perhaps the adoption of external collaborations, co-creations, alliances, and licenses will give a positive turnaround.

The company expects to submit to the FDA its semaglutide, the once-weekly injectable GLP1, which registered positive data later this quarter.

Novo Nordisk A/S (ADR) (NYSE:NVO) last trading session closed at $35.54, a decline of $0.12 or 0.34%.

Follow Novo Nordisk A S (NYSE:NVO)
Trade (NYSE:NVO) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.

Loading Comments...